Lightnews — Scholar-powered news

Peter Hall

@peterhall001.bsky.social

210 followers 160 following 17 posts

Breast Oncologist and Professor of Cancer Informatics, Edinburgh | Health Economics | Real World Evidence | https://cancer-data.ecrc.ed.ac.uk/

Videos

Sir Peter Geoffrey Hall was an English town planner, urbanist and geographer. He was the Bartlett Professor of Planning and Regeneration at The Bartlett, University College London and president of both the Town and Country Planning Association and the Regional Studies Association. Hall was one of the most prolific and influential urbanists of the twentieth century. .. more

Mathematics 45%

Economics 28%

Posts Media Videos Starter Packs

Pinned

Peter Hall @peterhall001.bsky.social · Nov 18

Looking for collaborators to work on federated Real World Evidence studies related to cancer. We are building our infrastructure and need high value demonstaror projects. #OHDSI #EHDEN #OMOP #RWE please get in touch

Edinburgh Cancer Informatics @cancerdataedin.bsky.social · Nov 18

DataLoch, in collaboration with ECi are proud to announce our membership of the UK RWE Network. Operated by HDR UK, we aim to prove the potential of Observational Medical Outcomes Partnership (OMOP) and the Common Data Model (CDM).

Find out more below👇🏼
t.co/rj89DIgT4b

1 2 5

Reposted by Peter Hall

Peter Tennant @pwgtennant.bsky.social · Sep 3

The TARGET reporting guidelines for target trial emulation studies have arrived!

#EpiSky #CausalSky

jamanetwork.com/journals/jam...

TARGET 2025 Statement

This Special Communication introduces the Transparent Reporting of Observational Studies Emulating a Target Trial (TARGET) 2025 guideline, a consensus-based guidance for reporting observational studie...

jamanetwork.com

1 9 23

Peter Hall @peterhall001.bsky.social · Aug 29

Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial - The Lancet www.thelancet.com/journals/lan...

The addition of adjuvant chemotherapy to hormonotherapy conferred no survival benefit in women aged 70 years and above with a GGI high-risk oestrogen receptor-positive HER2-negative breast cancer, and...

www.thelancet.com

Reposted by Peter Hall

The Health Foundation @healthfoundation.bsky.social · Aug 29

In this blog, Jack Elliott and Elaine Kelly examine trends in unpaid overtime among NHS staff since 2019 and consider the implications for future productivity.

Read more ⬇️
https://bit.ly/4mILY3C

Bar chart of total unpaid hours worked across the NHS, expressed as full-time equivalent staff, 2019 to 2024 showing unpaid overtime in 2024 equivalent to workload of at least 33,000 full-time staff.

4 1

Peter Hall @peterhall001.bsky.social · Aug 21

Preprint "The C-Index Multiverse" arxiv.org/abs/2508.14821

The C-index Multiverse

Quantifying out-of-sample discrimination performance for time-to-event outcomes is a fundamental step for model evaluation and selection in the context of predictive modelling. The concordance index, ...

arxiv.org

Reposted by Peter Hall

Darren Dahly @statsepi.bsky.social · Aug 12

Target trial emulation is an important, useful idea, but we must remain careful to not allow novices to think it's a magical shortcut to causal inference. Nor can we lose sight of the *main* thing that separates randomized from non-randomized studies.

POTENTIAL RISKS OF TARGET TRIAL
TERMINOLOGY
There are risks that the term target trial emulation (TTE)
might mislead readers without methodological training. We
believe some readers may assume TTE represents a distinct
form of observational study design, rather than a framework
to help researchers identify and avoid self-inflicted errors in
observational studies. We are particularly concerned that
claims to have emulated an RCT will be mistaken for a claim
to have successfully emulated an RCT. The latter statement
implies that the inference is of a comparable standard to a
well-conducted RCT. To be certain, the TTE framework (2),
used correctly, will help investigators specify estimands,
and sidestep avoidable selection bias, but we are probably
more pessimistic than Schwarze et al. (1) about the ability
of ‘‘advanced methods’’ to address the threat of other
sources of bias.

However, the difference in how
randomization accounts for confounding vs. ‘‘advanced
methods’’ like covariate adjustment, weighting, etc. is a
difference in kind, not in degree. This is because
randomization is guaranteed to eliminate confounding for
some key estimands, and to do so in a manner that
predominantly rests on our trust in a potentially verifiable
randomization process. In contrast, acting on the effect
estimate returned from an NRSI requires us to trust in the decisions and competence of the investigator, and even then,
no guarantee is possible, even in relatively simple sets of
relationships among a small set of potential covariates.
This distinction will be obvious to methodological experts,
but they only constitute a small proportion of researchers
and research-consumers

2 5 19

Reposted by Peter Hall

Edinburgh Cancer Informatics @cancerdataedin.bsky.social · Nov 18

Reposted by Peter Hall

Ben Harrap @bharrap.bsky.social · Jul 16

Introducing my new #rstats package {kitchensink}

Not sure what the right model to fit is? Should you allow random intercepts, slopes, both? What do Bayesian methods say?

Just call {kitchensink::throw} to fit every possible model and see how your results differ!

11 22 140

Peter Hall @peterhall001.bsky.social · Apr 27

www.nature.com/articles/s41...

Less-frequent surveillance is noninferior to annual mammography - Nature Reviews Clinical Oncology

Nature Reviews Clinical Oncology - Less-frequent surveillance is noninferior to annual mammography

www.nature.com

Reposted by Peter Hall

Edinburgh Cancer Informatics @cancerdataedin.bsky.social · Mar 7

We're hiring!
A vacancy has opened up in the team for the position of Post-Doctoral Research Fellow. 🔬 🧑🏼‍💻

If this sounds like something you'd be interested in, details can be found on our website below. 👇

cancer-data.ecrc.ed.ac.uk/2025/03/07/r...

Reposted by Peter Hall

Cancer Research UK Scotland Institute @cruk-si.bsky.social · Feb 27

Haven't registered your place for the Beatson International Cancer Conference 2025 yet? Find out what delegates had to say about last year's event

📅Register by 21 March: beatsonconference.org

#BICC2025

10 11

Peter Hall @peterhall001.bsky.social · Feb 21

Today is the 4th Edinburgh Breast Cancer Special Symposium #EBCSS25 www.ebcss.org

Home | EBCSS 2025 Edinburgh

EBCSS Edinburgh International Breast Cancer Conference

www.ebcss.org

Peter Hall @peterhall001.bsky.social · Feb 16

A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer www.nature.com/articles/s41...

A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer - npj Breast Cancer

npj Breast Cancer - A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer

www.nature.com

Peter Hall @peterhall001.bsky.social · Jan 31

Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): a multicentre, randomised, phase 3, non-inferiority trial - The Lancet www.thelancet.com/journals/lan...

Reposted by Peter Hall

Elisabetta Bonzano MD, PhD @elisabettabonzano.bsky.social · Jan 30

📌 Adjuvant Atezolizumab for Early Triple-Negative Breast CancerThe ALEXANDRA/IMpassion030 Randomized Clinical Trial

jamanetwork.com/journals/jama/…
@oncoalert.bsky.social

1 2 7

Reposted by Peter Hall

Cancer Research UK @cancerresearchuk.org · Jan 22

Together with the NIHR (National Institute for Health and Care Research), the EPSRC, Health Data Research UK (HDR UK) and ADR UK (Administrative Data Research UK), we’re announcing a £10m programme which will help identify individual cancer risk 🙌

Read more 👉 cruk.ink/42q0aaY

£10m funding for new programme to help identify individual cancer risk - Cancer Research UK - Cancer News

Today, Cancer Research UK, the NIHR and the EPSRC are announcing £10 million to create the Cancer Data-Driven Detection programme

cruk.ink

20 47

Reposted by Peter Hall

Karin Purshouse @karinpurshouse.bsky.social · Jan 6

So happy to share the latest study from NOTCH led by Dr Karen Mactier from @NHS_Lothian @UofGlasgow, looking at UK-wide practice in managing a rare cancer, uterine sarcoma

👇👇👇

pubmed.ncbi.nlm.nih.gov/39725428/

TOURISM study (Treatment Outcomes in UteRIne SarcoMa): a 10-year retrospective evaluation of practice in the UK - PubMed

Our data highlight the diversity in patient management in uterine sarcoma and a marked survival advantage for patients diagnosed with stage I disease. These data highlight the importance of a multidis...

pubmed.ncbi.nlm.nih.gov

4 6

Reposted by Peter Hall

Katie Spencer @katiespencer.bsky.social · Jan 6

Are you a health economist, epidemiologist or data scientist with experience using routine healthcare data? Interested in equity in cancer care? Come and join this exciting @nihr.bsky.social funded project! Work with a range of stakeholders and build your skills. jobs.leeds.ac.uk/Vacancy.aspx...

Job Opportunity at University of Leeds: Research Fellow

Are you an ambitious researcher looking for your next challenge? Do you have a background in economics, econometrics, statistics, epidemiology or health data science? Are you interested in working wit...

jobs.leeds.ac.uk

1 5 7

Reposted by Peter Hall

Richard Simcock @breastdocuk.bsky.social · Dec 11

4w Denosumab or 12w

The efficacy results of the REDUSE study are not mature yet but the tox results are in

Less drug - fewer tox events

ONJ all grades 8.1 vs 5.2%
#SABCS24

1 4 7

Peter Hall @peterhall001.bsky.social · Dec 10

#SABCS24 FDA session highlighting need to consider Minimum Effictive Dose, not just Maximum Tolerated Dose. Reminds me of the GO2 trial in gastric ca last decade. Breast cancer drug development catching up? jamanetwork.com/journals/jam...

Efficacy of Reduced-Intensity Chemotherapy Among Older and Frail Patients With Advanced Gastroesophageal Cancer

This randomized clinical trial assesses the efficacy of reduced-intensity chemotherapy for patient quality of life and cancer control in the treatment of older and/or frail patients.

jamanetwork.com

1 2 7

Peter Hall @peterhall001.bsky.social · Dec 2

The Sudlow Review on the challenges and opportunities for using UK linked healthcare data for research www.hdruk.ac.uk/helping-with...

www.hdruk.ac.uk

1 1

Reposted by Peter Hall

Toni Choueiri, MD @drchoueiri.bsky.social · Nov 30

Our latest in @naturecomms.bsky.social from @danafarber.bsky.social / @mskcc.bsky.social collaboration: AI to extract cancer outcomes in EMR!

www.nature.com/articles/s41...

1 11 37

Peter Hall @peterhall001.bsky.social · Nov 29

Very good to see more de-escalation trials publishing in HER2 positive early breast cancer. Here the HELEN-006 trial. www.thelancet.com/journals/lan...

De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006)...

These findings might suggest a potential advantage of nab-paclitaxel combined with trastuzumab and pertuzumab compared with the standard regimen in neoadjuvant therapy for patients with HER2-positive ...

www.thelancet.com

3 10

Reposted by Peter Hall

Kristoffer Stewart @journal-kristoffer.bsky.social · Nov 28

📣 Check out this recent study:

UK national observational cohort study investigating Tolerance of Anti-cancer Systemic Therapy in the Elderly: the TOASTIE study

From @drmarkbaxter.bsky.social and colleagues: bmjoncology.bmj.com/content/3/1/...
#cancer #chemotherapy

UK national observational cohort study investigating Tolerance of Anti-cancer Systemic Therapy in the Elderly: the TOASTIE study

Objective The Cancer and Aging Research Group (CARG) score was developed to predict severe chemotherapy-induced toxicity risk in older adults; validation study results have varied. The Tolerance of An...

bmjoncology.bmj.com

1 4 8

Peter Hall @peterhall001.bsky.social · Nov 27

This is how we should be doing Oncology trials - the Dutch SONIA trial looking at treatment sequencing of CDK 4/6 inhibitors in advanced breast cancer. A self funding efficiency trial! #oncsky www.nature.com/articles/s41...

Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer - Nature

The phase 3 SONIA trial challenges the benefits of using cyclin-dependent kinase 4 and 6 inhibitors as a first-line compared with second-line treatment.

www.nature.com

1 8 21

Peter Hall @peterhall001.bsky.social · Nov 23

Any good starter packs out there for folks using routine healthcare data for cancer research? #oncsky #cancerinformatics #causalinference

1 5

Reposted by Peter Hall

Owen Jackson @owenjackson.bsky.social · Nov 21

🧵

New research published today by the OECD:

💷 #Cancer adds £14.4bn to annual UK #health expenditure - even accounting for other health costs those who don't get cancer go on to require

📈Without action, per capita costs could increase by >50% by 2050

1/

news.cancerresearchuk.org/2024/11/21/t...

The cost of cancer: what does it mean for the UK’s growth mission - Cancer Research UK - Cancer News

The OECD's report on the economic impact of cancer makes it clear the UK government needs to focus on tackling the disease.

news.cancerresearchuk.org

1 15 26

Reposted by Peter Hall

London School of Hygiene & Tropical Medicine @lshtm.bsky.social · Nov 21

Patients with #cancer favour evidence of success over quick drug approvals.

Ajay Aggarwal explains while offering patients new treatment options is crucial, survey suggests not all patients want faster cancer drug approvals without certainty they work. #PublicHealth

www.lshtm.ac.uk/newsevents/n...

3 7

Peter Hall @peterhall001.bsky.social · Nov 21

This is a very thorough review!

Reposted by Peter Hall

Peter Hall @peterhall001.bsky.social · Nov 19

👍